OMER - Omeros: Troubled Company Working Its Way Out Of The Morass
2024-07-19 00:11:42 ET
Summary
- During its annual meeting, Omeros described its recent financial moves to extend its debt maturities.
- Narsoplimab, OMER's lead therapy, has struggled to advance past late-stage trials.
- With its lead asset stuck in an FDA approval thicket, the Company is a high-risk investment.
This is my 25th Omeros ( OMER ) article, following 02/2024's "Omeros: Still Worth A Look Despite Narsoplimab Woes" ("Woes"). In Woes, I rated Omeros as a "Hold". Since that time, it has enjoyed a nice bump ~30%. In the conclusion to Woes, I observed, "it is easier to support a bear thesis for Omeros than it is to support a bull thesis."...
Omeros: Troubled Company Working Its Way Out Of The Morass